Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	1. To evaluate the efficacy of 2-Deoxy-D-Glucose (2-DG) as an adjunctive therapy to standard of care (SoC); in comparison to SoC alone; in the acute treatment of moderate to severe COVID-19 patients <br/ >2. To evaluate the safety of 2-DG as an adjunctive therapy to standard of care (SoC); in comparison to SoC alone; in the acute treatment of moderate to severe COVID-19 patients <br/ >Timepoint: entire duration of Trial	1. To evaluate the efficacy of 2-Deoxy-D-Glucose (2-DG) as an adjunctive therapy to standard of care (SoC); in comparison to SoC alone; in the acute treatment of moderate to severe COVID-19 patients <br/ >2. To evaluate the safety of 2-DG as an adjunctive therapy to standard of care (SoC); in comparison to SoC alone; in the acute treatment of moderate to severe COVID-19 patients <br/ >Timepoint: entire duration of Trial
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
Jan. 15, 2021, 12:45 a.m.	oms	1. To evaluate the efficacy of 2-Deoxy-D-Glucose (2-DG) as an adjunctive therapy to standard of care (SoC); in comparison to SoC alone; in the acute treatment of moderate to severe COVID-19 patients <br/ >2. To evaluate the safety of 2-DG as an adjunctive therapy to standard of care (SoC); in comparison to SoC alone; in the acute treatment of moderate to severe COVID-19 patients <br/ >Timepoint: entire duration of Trial	1. To evaluate the efficacy of 2-Deoxy-D-Glucose (2-DG) as an adjunctive therapy to standard of care (SoC); in comparison to SoC alone; in the acute treatment of moderate to severe COVID-19 patients <br/ >2. To evaluate the safety of 2-DG as an adjunctive therapy to standard of care (SoC); in comparison to SoC alone; in the acute treatment of moderate to severe COVID-19 patients <br/ >Timepoint: entire duration of Trial